Hisamitsu Pharmaceutical Co., Inc. (HPX.F)
- Previous Close
25.40 - Open
25.60 - Bid --
- Ask --
- Day's Range
25.60 - 25.60 - 52 Week Range
21.00 - 28.80 - Volume
75 - Avg. Volume
0 - Market Cap (intraday)
1.874B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
14.14 - EPS (TTM)
1.81 - Earnings Date Jul 10, 2025
- Forward Dividend & Yield 0.56 (2.20%)
- Ex-Dividend Date Aug 28, 2025
- 1y Target Est
--
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
www.global.hisamitsu--
Full Time Employees
February 28
Fiscal Year Ends
Sector
Recent News: HPX.F
View MorePerformance Overview: HPX.F
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HPX.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HPX.F
View MoreValuation Measures
Market Cap
1.87B
Enterprise Value
1.11B
Trailing P/E
14.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.97
Price/Book (mrq)
1.10
Enterprise Value/Revenue
1.16
Enterprise Value/EBITDA
5.14
Financial Highlights
Profitability and Income Statement
Profit Margin
13.95%
Return on Assets (ttm)
3.52%
Return on Equity (ttm)
8.16%
Revenue (ttm)
156.01B
Net Income Avi to Common (ttm)
21.76B
Diluted EPS (ttm)
1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
129.12B
Total Debt/Equity (mrq)
1.38%
Levered Free Cash Flow (ttm)
-379.38M